NCT00262990

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 829 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to assess the safety and efficacy of patupilone compared to pegylated liposomal doxorubicin. Additionally, this study will assess the ability of patupilone to extend the survival time and potential beneficial effects in women who have nonresponsive or recurrent ovarian, primary fallopian, or primary peritoneal cancer.

Conditions

• Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Neoplasms

Interventions

Type	Name	Description
DRUG	EPO906 (Patupilone)
DRUG	doxorubicin

Timeline

• Start date: 2005-11-01
• Primary completion: 2010-02-01
• First posted: 2005-12-07
• Last updated: 2020-12-17

Locations

149 sites across 12 countries: United States, Australia, Canada, Denmark, Finland, France, Greece, Italy, Poland, South Africa, Spain, United Kingdom